{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:18:09Z","timestamp":1789532289230,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd001287.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000}}],"reference-count":116,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001287.pub6","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T20:46:35Z","timestamp":1558385195000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2020","author":[{"given":"Phillippa","family":"Poole","sequence":"first","affiliation":[{"name":"University of Auckland; Department of Medicine; Private Bag 92019 Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavin","family":"Sathananthan","sequence":"additional","affiliation":[{"name":"St George's, University of London; Population Health Research Institute; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fortescue","sequence":"additional","affiliation":[{"name":"St George's, University of London; Cochrane Airways, Population Health Research Institute; London UK SW17 0RE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"10.1002\/14651858.CD001287.pub6-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000196540","article-title":"Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial","volume":"63","author":"Allegra","year":"1996","journal-title":"Respiration"},{"issue":"111 Suppl","key":"10.1002\/14651858.CD001287.pub6-BIB0002|cit2","first-page":"93","article-title":"Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study","volume":"61","author":"Multicenter Study Group","year":"1980","journal-title":"European Journal of Respiratory Disease"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0003|cit3","first-page":"12","article-title":"Effect of oral N-acetylcysteine in COPD - a randomised controlled trial","volume":"14","author":"Bachh","year":"2007","journal-title":"JK-Practitioner"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0004|cit4","first-page":"405","article-title":"Oral acetylcysteine reduces exacerbation rate in chronic bronchitis; report of a trial organized by the Swedish Society for Pulmonary Diseases","volume":"64","author":"Boman","year":"1983","journal-title":"European Journal of Respiratory Disease"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0005|cit5","first-page":"155","article-title":"Clinical effectiveness and tolerance of cithiolone in the prophylaxis of acute infective exacerbations in patients suffering from chronic bronchitis","volume":"17","author":"Bontognali","year":"1991","journal-title":"Acta Therapeutica"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0006|cit6","first-page":"467","article-title":"Comparison between acetylcysteine and placebo in the long term treatment of chronic bronchitis","volume":"140","author":"Borgia","year":"1981","journal-title":"Gazzetta Medica Italiana"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000194928","article-title":"Effect of long-term treatment with sobrerol on the exacerbations of chronic bronchitis","volume":"50","author":"Castiglioni","year":"1986","journal-title":"Respiration"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0008|cit8","first-page":"715","article-title":"Long-term treatment of chronic bronchitis for two years with ambroxol (Mucosolvan) retard capsules. Results of a double blind trial including 180 patients","volume":"42","author":"Cegla","year":"1988","journal-title":"Praxis Klinik der Pneumologie"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0009|cit9","first-page":"121","article-title":"I farmaci attivi sul muco nel trattamento di fondo della bronchite cronica","volume":"116","author":"Cremonini","year":"1986","journal-title":"La Clinica Terapeutica"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Calverley PMA Page C Dal Negro RW Fontana G Iversen M Cicero AF Effect of erdosteine in moderately severe COPD patients European Respiratory Journal 2018 PA776","DOI":"10.1183\/13993003.congress-2018.PA776"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Calverley PMA Page C Dal Negro RW Fontana G Iversen M Cicero AF Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients Respirology 2017 49","DOI":"10.1111\/resp.13206_118"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0012|cit12","first-page":"PA1495","article-title":"Efficacy and safety of erdostein in COPD: results of a 12-month prospective, multinational study","volume":"46","author":"Dal Negro","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1700711","DOI":"10.1183\/13993003.00711-2017","article-title":"Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study","volume":"50","author":"Dal Negro","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Dal Negro RW Wedzicha JA Iversen MI Fontana G Page C Cicero AF Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine) European Respiratory Journal 2017 PA675","DOI":"10.1183\/1393003.congress-2017.PA675"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"De Backer J Vos W Van Holsbeke C Vinchurkar S Claes R Parizel P Double blind, randomized, two-way crossover, pilot study to assess the effect of high dose N-acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging American Journal of Respiratory and Critical Care Medicine 2013","DOI":"10.2147\/COPD.S49307"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/COPD.S49307","article-title":"Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients","volume":"8","author":"Backer","year":"2013","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"9470","key":"10.1002\/14651858.CD001287.pub6-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1034\/j.1399-3003.1999.13d22.x","article-title":"N isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis","volume":"13","author":"Ekberg-Jansson","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2147\/COPD.S103105","article-title":"Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study","volume":"11","author":"Fukuchi","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0020|cit20","first-page":"PA4359","article-title":"Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study","volume":"46","author":"Ichinose","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00606554","article-title":"A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis","volume":"9","author":"Grassi","year":"1976","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0022|cit22","first-page":"17","volume":"48","author":"Grassi","year":"1994","journal-title":"Italian Journal of Chest Disease"},{"issue":"10","key":"10.1002\/14651858.CD001287.pub6-BIB0023|cit23","first-page":"395","article-title":"Long-term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control","volume":"39","author":"Grillage","year":"1985","journal-title":"British Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0954-6111(05)80337-3","article-title":"Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis","volume":"88","author":"Hansen","year":"1994","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/030006058401200312","article-title":"Efficacy and tolerability of oral acetylcysteine (fabrol) in chronic bronchitis: a double-blind placebo controlled trial","volume":"12","author":"Jackson","year":"1984","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0026|cit26","first-page":"799","article-title":"High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial","volume":"11","author":"Johnson","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pupt.2003.08.004","article-title":"Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multi-center, placebo-controlled study (the AMETHIST trial)","volume":"17","author":"Malerba","year":"2004","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD001287.pub6-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/thx.40.11.832","article-title":"Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction","volume":"40","author":"British Thoracic Society Research Committee","year":"1985","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0029|cit29","unstructured":"Meister R Long-term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: a double-blind, placebo controlled study Unpublished source 1986"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.2147\/COPD.S117652","article-title":"Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial","volume":"11","author":"Beeh","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0031|cit31","first-page":"351","article-title":"Efficacy and tolerability of myrtol standardized in long-term treatment of chronic bronchitis. A double-blind, placebo-controlled study. Study Group Investigators","volume":"49","author":"Meister","year":"1999","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0032|cit32","first-page":"143","article-title":"The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study","volume":"30","author":"Moretti","year":"2004","journal-title":"Drugs Under Experimental and Clinical Research"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0033|cit33","first-page":"381S","article-title":"Long-term administration of N-acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study","volume":"14 Suppl","author":"Nowak","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000195274","article-title":"Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial","volume":"51 Suppl 1","author":"Olivieri","year":"1987","journal-title":"Respiration"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0007-0971(87)90182-3","article-title":"Oral fabrol (oral n-acetyl-cysteine) in chronic bronchitis","volume":"81","author":"Parr","year":"1987","journal-title":"British Journal of Diseases of the Chest"},{"issue":"6","key":"10.1002\/14651858.CD001287.pub6-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000029447","article-title":"N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD","volume":"66","author":"Pela","year":"1999","journal-title":"Respiration"},{"issue":"Suppl","key":"10.1002\/14651858.CD001287.pub6-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1378\/chest.97.2.24S","article-title":"Summary of the national mucolytic study","volume":"97","author":"Morgan","year":"1990","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1378\/chest.97.1.75","article-title":"The national mucolytic study: results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis","volume":"97","author":"Petty","year":"1990","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1183\/09031936.93.01040351","article-title":"Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis","volume":"1","author":"Rasmussen","year":"1988","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0041|cit40","first-page":"S107","article-title":"Role of n-acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease","volume":"45","author":"Roy","year":"2013","journal-title":"Indian Journal of Pharmacology Conference Publication"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0040|cit41","first-page":"95","article-title":"Evaluation of effect of N-acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease","volume":"3","author":"Roy","year":"2014","journal-title":"International Journal of Medical and Applied Sciences"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0042|cit42","first-page":"1356","article-title":"Demographic and clinical determinants of response to N-acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study","volume":"26 (S49)","author":"Chavannes","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.rmed.2008.11.003","article-title":"Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis","volume":"103","author":"Schermer","year":"2009","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001287.pub6-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1378\/chest.13-2784","article-title":"Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD","volume":"146","author":"Tse","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1378\/chest.12-2357","article-title":"High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study","volume":"144","author":"Tse","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0047|cit46","first-page":"P2105","article-title":"The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial","volume":"40 Suppl 56","author":"Tse","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0046|cit47","first-page":"A2448","article-title":"The effect of high dose N-acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease - a one-year, double blind, randomized, placebo-controlled trial","volume":"187","author":"Tse","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1465-9921-10-69","article-title":"Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial","volume":"10","author":"Worth","year":"2009","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Worth H Schacher C Dethlefsen U Effects of concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: a placebo-controlled double-blind trial European Respiratory Society 20th Annual Congress; 2010 Sep 18-22; Barcelona 2010","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A4418"},{"issue":"40","key":"10.1002\/14651858.CD001287.pub6-BIB0050|cit50","first-page":"870","article-title":"Evaluation on effectiveness of salmeterol\/fluticasone propionate combined with N-acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]","volume":"40","author":"Xu","year":"2014","journal-title":"Journal of Jilin University Medicine Edition"},{"issue":"9629","key":"10.1002\/14651858.CD001287.pub6-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled trial","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Papi A Brusselle G Sergio F Pannacci M Zheng J Criner G Blood eosinophils and smoking history affect outcome with high dose N-acetylcysteine treatment in COPD European Respiratory Journal 2017 PA1066","DOI":"10.1183\/1393003.congress-2017.PA1066"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.rmed.2018.12.014","article-title":"Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post-hoc analysis of the PANTHEON study","volume":"147","author":"Papi","year":"2019","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0054|cit54","first-page":"186","article-title":"Long term treatment with n-acetylcysteine reduces moderate-severe exacerbations of chronic obstructive pulmonary disease","volume":"21","author":"Sergio","year":"2016","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/15412555.2012.732628","article-title":"High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study","volume":"10","author":"Zheng","year":"2013","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0056|cit56","unstructured":"Zheng JP Wen FQ Bai CX Wan HY Kang J Chen P High-dose N-acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study European Respiratory Society 23rd Annual Congress; 2013 Sep 7-11; Barcelona 2013"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"issue":"33 Suppl","key":"10.1002\/14651858.CD001287.pub6-BIB0058|cit58","first-page":"58S","article-title":"Effects of N-acetylcysteine treatment during long term oxygen therapy (LTOT) in COPD patients. An open parallel-group study","volume":"18","author":"Baglioni","year":"2001","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0059|cit59","first-page":"277","article-title":"Neltenexine tablets in smoking and non-smoking patients with COPD. A double-blind, randomised, controlled study versus placebo","volume":"92","author":"Cattaneo","year":"2001","journal-title":"Minerva Medica"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0060|cit60","first-page":"69","article-title":"Mucolytic treatment of chronic bronchitis during two winter periods","volume":"90","author":"Andreasen","year":"1974","journal-title":"Scandinavian Journal of Respiratory Disease"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0061|cit61","first-page":"48","article-title":"Mucolytic treatment of chronic bronchitis during two winter periods","volume":"52","author":"Christensen","year":"1971","journal-title":"Scandinavian Journal of Respiratory Disease"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1378\/chest.70.4.506","article-title":"S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction","volume":"70","author":"Edwards","year":"1976","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD001287.pub6-BIB0063|cit63","first-page":"356","article-title":"Chronic obstructive lung diseases: the efficacy of cineole","volume":"44","author":"Habich","year":"1994","journal-title":"Therapiewoche"},{"issue":"6","key":"10.1002\/14651858.CD001287.pub6-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/rmed.2001.1066","article-title":"Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease","volume":"95","author":"Kasielski","year":"2001","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1055\/s-2005-865062","article-title":"Administration of N-acetylcysteine and vitamin C to augment antioxidant properties in patients with chronic bronchitis","volume":"130","author":"Lukas","year":"2005","journal-title":"Deutsche Medizinishe Wochenscrift"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0066|cit66","first-page":"110","article-title":"Treatment of chronic bronchitis with oral acetylcysteine, a double-blind study","volume":"61","author":"Maesen","year":"1980","journal-title":"European Journal of Respiratory Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001287.pub6-BIB0067|cit67","first-page":"90","article-title":"Assessment of efficacy and tolerability of the oral treatment of ambrosol in patients with chronic bronchitis","volume":"64","author":"Michnar","year":"1996","journal-title":"Pneumonologia i Alergologia Polska"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0068|cit68","unstructured":"Moretti M Ballabio M Effect of erdosteine on airflow obstruction and symptom recovery in severe COPD exacerbations [Abstract] European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam 2011 76s [P536]"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0069|cit69","first-page":"P293","article-title":"Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation [Abstract]","volume":"44","author":"Moretti","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3177\/jnsv.62.54","article-title":"Efficacy of ascorbic acid (vitamin C) and\/N-acetylcysteine (NAC) supplementation on nutritional and antioxidant status of male chronic obstructive pulmonary disease (COPD) patients","volume":"62","author":"Pirabbasi","year":"2016","journal-title":"Journal of Nutritional Science and Vitaminology"},{"issue":"2","key":"10.1002\/14651858.CD001287.pub6-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1378\/chest.109.2.348","article-title":"Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis","volume":"109","author":"Rubin","year":"1996","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0072|cit72","first-page":"PA544","article-title":"Effect of carbocysteine lysine salt on frequency of exacerbations in COPD patient treated with or without inhaled steroids","volume":"48","author":"Saibene","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD001287.pub6-BIB0073|cit73","first-page":"OC16","article-title":"N-Acetylcysteine combined with home based physical activity: effect on health related quality of life in stable COPD patients - a randomised controlled trial","volume":"10","author":"Salve","year":"2016","journal-title":"Journal of Clinical and Diagnostic Research"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0074|cit74","first-page":"PA4299","article-title":"Treatment of chronic obstructive pulmonary disease in clean-up workers of the Chornobyl NPP accident in the remote period after irradiation with additional 6 month prescription combination of ambroxol and essential phospholipids","volume":"48","author":"Sushko","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"457","DOI":"10.33145\/2304-8336-2015-20-457-466","article-title":"Optimization of chronic obstructive pulmonary disease treatment in clean-up workers of the Chornobyl NPP accident in the remote period after irradiation","volume":"20","author":"Sushko","year":"2015","journal-title":"Problemy Radiatsiinoi Medytsyny Ta Radiobiolohii"},{"issue":"11","key":"10.1002\/14651858.CD001287.pub6-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/j.1532-5415.2007.01373.x","article-title":"Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease","volume":"55","author":"Tatsumi","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0077|cit77","unstructured":"Tatsumi K Fukuchi Y Carbocisteine reduces the frequency of exacerbations in patients with COPD: findings from the PEACE study American Thoracic Society International Conference; 2007; May 18-23; San Francisco 2007 C97"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD001287.pub6-BIB0078|cit78","first-page":"A57","article-title":"The mucolytic effect on quality of life in patients with COPD","volume":"163","author":"Velazquez","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0079|cit79","first-page":"554","article-title":"Treatment of COPD: benefit of 1.8 cineole as co medication confirmed","volume":"2","author":"Wilhelmi","year":"2010","journal-title":"Journal Pharmakol U Ther"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0080|cit80","unstructured":"Hussain A Rizvi W Comparative Evaluation of Efficacy and Safety Profile of Antioxidants-N-Acetyl-L-Cysteine(NAC) and Superoxide Dismutase (SOD) Supplementation in Patients of COPD Clinical Trials Registry - India 2015"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0081|cit81","unstructured":"Early Intervention With Carbocysteine and Low Dose Theophylline in Chinese Patients With Chronic Obstructive Pulmonary Disease Chinese Clinical Trials Registry 2018"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0082|cit82","unstructured":"Zhou Y Ran P Long-Term Regular Treatment of Early COPD With Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Study With Acetylcysteine Effervescent Tablets Chinese Clinical Trial Registry 2017"},{"issue":"17","key":"10.1002\/14651858.CD001287.pub6-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1426-31","DOI":"10.1001\/jama.1997.03550170056032","article-title":"Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial","volume":"278","author":"Anzueto","year":"1997","journal-title":"Journal of American Medical Association"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0084|cit84","unstructured":"Ballabio M Nicola M Moretti M Long-term use of antioxidant mucolytic erdosteine is especially beneficial in patient with more severe COPD European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin 2008 abstract ERS08L1_678"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-2-1","article-title":"Simpson's paradox and calculation of number needed to treat from meta-analysis","volume":"2","author":"Cates","year":"2002","journal-title":"BMC Medical Research Methodology"},{"issue":"137","key":"10.1002\/14651858.CD001287.pub6-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1183\/16000617.00002215","article-title":"Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis","volume":"24","author":"Cazzola","year":"2015","journal-title":"European Respiratory Review"},{"issue":"6","key":"10.1002\/14651858.CD001287.pub6-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1164\/ajrccm.156.6.9612096","article-title":"Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease","volume":"156","author":"Collet","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1378\/chest.14-1677","article-title":"Prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline","volume":"147","author":"Criner","year":"2015","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD001287.pub6-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.hrtlng.2016.12.004","article-title":"The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: a meta-analysis and systematic review","volume":"46","author":"Fowdar","year":"2017","journal-title":"Heart and Lung"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0090|cit90","unstructured":"Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 goldcopd.org\/wp-content\/uploads\/2018\/11\/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf"},{"issue":"2","key":"10.1002\/14651858.CD001287.pub6-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0149-2918(00)88479-9","article-title":"Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials","volume":"22","author":"Grandjean","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/phrs.1999.0647","article-title":"Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis","volume":"42","author":"Grandjean","year":"2000","journal-title":"Pharmacology Research"},{"issue":"10","key":"10.1002\/14651858.CD001287.pub6-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/thx.42.10.773","article-title":"A measure of quality of life for clinical trials in chronic lung disease","volume":"42","author":"Guyatt","year":"1987","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0094|cit94","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration, 2011"},{"issue":"6","key":"10.1002\/14651858.CD001287.pub6-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"American Review of Respiratory Disease"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"issue":"3","key":"10.1002\/14651858.CD001287.pub6-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD001287.pub6-BIB0098|cit98","first-page":"600","article-title":"Mucolytic and antioxidant agents for exacerbations of chronic obstructive pulmonary disease: a meta-analysis","volume":"38","author":"Li","year":"2015","journal-title":"Chinese Journal of Tuberculosis and Respiratory Diseases"},{"issue":"Suppl 51","key":"10.1002\/14651858.CD001287.pub6-BIB0099|cit99","first-page":"557s","article-title":"Prevention of COPD exacerbations and reduction of health care utilization with erdosteine","volume":"30","author":"Moretti","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0100|cit100","unstructured":"National Institute for Health and Care Excellence Chronic obstructive pulmonary disease in over 16s: diagnosis and management www.nice.org.uk\/guidance\/ng115"},{"issue":"3","key":"10.1002\/14651858.CD001287.pub6-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","article-title":"Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society","volume":"155","author":"Qaseem","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001287.pub6-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/CBB:43:1:167","article-title":"Oxidative stress in the pathogenesis of chronic obstructive pulmonary disease; cellular and molecular mechanisms","volume":"43","author":"Rahman","year":"2005","journal-title":"Cell Biochemistry and Biophysics"},{"issue":"9518","key":"10.1002\/14651858.CD001287.pub6-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0140-6736(06)68516-4","article-title":"COPD: the dangerous underestimate of 15%","volume":"367","author":"Rennard","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0104|cit104","first-page":"859-65","article-title":"Mucolytics, expectorants, and mucokinetic medications","volume":"52","author":"Rubin","year":"2007","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2213-0802-2-6","article-title":"Secretion properties, clearance, and therapy in airway disease","volume":"2","author":"Rubin","year":"2014","journal-title":"Translational Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001287.pub6-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1034\/j.1399-3003.2000.16b12.x","article-title":"The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review","volume":"16","author":"Stey","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD001287.pub6-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001001.pub3","article-title":"Lung volume reduction surgery for diffuse emphysema","author":"Agteren","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001287.pub6-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"pii: 1602265","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0109|cit109","unstructured":"World Health Organization The top 10 causes of death www.who.int\/mediacentre\/factsheets\/fs310\/en\/"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0110|cit110","unstructured":"Yang IA Brown JL George J Jenkins S McDonald CF McDonald V The COPD-X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease. Version 2.53 copdx.org.au\/wp-content\/uploads\/2018\/11\/COPDX-V2-55-Aug-2018.pdf"},{"issue":"4","key":"10.1002\/14651858.CD001287.pub6-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001287","article-title":"The effect of mucolytic agents on exacerbation frequency in chronic bronchitis","author":"Poole","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001287.pub6-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001287","article-title":"Mucolytic agents for chronic bronchitis","author":"Poole","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001287.pub6-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.322.7297.1271","article-title":"Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review","volume":"322","author":"Poole","year":"2001","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD001287.pub6-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001287.pub2","article-title":"Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease","author":"Poole","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD001287.pub6-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001287","article-title":"Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease","author":"Poole","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD001287.pub6-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001287.pub5","article-title":"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease","author":"Poole","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001287.pub6\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T19:26:53Z","timestamp":1694892413000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001287.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":116,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001287.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,20]]}}}